Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Swedish Orphan Biovitrum AB (OTC: BIOVF).

Full DD Report for BIOVF

You must become a subscriber to view this report.


Recent News from (OTC: BIOVF)

Swedish Orphan Biovitrum Acquires Synagis U.S. Rights
The following slide deck was published by Swedish Orphan Biovitrum AB in conjunction with this Read more ...
Source: SeekingAlpha
Date: November, 13 2018 23:25
Swedish Orphan Biovitrum AB's (BIOVF) CEO Guido Oelkers on Merger & Acquisition Conference - Transcript
Swedish Orphan Biovitrum AB (BIOVF) Merger & Acquisition Conference Call November 13, 2018 8:00 AM ET Executives Guido Oelkers – Chief Executive Officer Henrik Stenqvist – Chief Financial Officer Milan Zdravkovic – Head-R&D Analysts Peter Sehest...
Source: SeekingAlpha
Date: November, 13 2018 23:15
Sobi to acquire U.S. rights to AstraZeneca's Synagis and half interest in MEDI8897 for $1.5B
Swedish Orphan Biovitrum AB ( OTCPK:BIOVF ) (Sobi) has agreed to acquire the U.S. rights to AstraZeneca's (NYSE: AZN ) RSV med Synagis (palivizumab) and 50% of the future U.S. earnings of candidate MEDI8897 for $1.0B in cash and and $500M in newly issued Sobi stock. More news on: Swedish...
Source: SeekingAlpha
Date: November, 13 2018 08:34
Sobi(TM) to Acquire Synagis® US Rights From AstraZeneca - Creates a Platform for Global Growth
STOCKHOLM , Nov. 13, 2018 /PRNewswire/ --  Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) has entered into agreements to acquire the perpetual rights to Synagis® (palivizumab) in the US from AstraZeneca and to participate in 50 per cent of the future earnings of t...
Source: PR Newswire
Date: November, 13 2018 02:22
Swedish Orphan Biovitrum AB (BIOVF) CEO Guido Oelkers on Q3 2018 Results - Earnings Call Transcript
Swedish Orphan Biovitrum AB (BIOVF) Q3 2018 Earnings Conference Call October 31, 2018 08:00 ET Executives Guido Oelkers - President & CEO Henrik Stenqvist - CFO Armin Reininger - Head, Medical & Scientific Affairs Analysts Kyung Yang - Jefferies Peter Sehested - H...
Source: SeekingAlpha
Date: November, 01 2018 01:04
Swedish Orphan Biovitrum AB 2018 Q3 - Results - Earnings Call Slides
The following slide deck was published by Swedish Orphan Biovitrum AB in conjunction with their 2018 Q3 earnings Read more ...
Source: SeekingAlpha
Date: October, 31 2018 10:41
Swedish Orphan Biovitrum AB reports Q3 results
Swedish Orphan Biovitrum AB ( OTCPK:BIOVF ): Q3 GAAP EPS of SEK2.31. More news on: Swedish Orphan Biovitrum AB, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: October, 31 2018 05:40
Platinum Asset Management Quarterly Report September 30, 2018
Read more ...
Source: SeekingAlpha
Date: October, 25 2018 06:00
Invitation - Presentation of Sobi's Q3 2018 Results
STOCKHOLM , Oct. 23, 2018 /PRNewswire/ -- On 31 October, at 08:00 CET , Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the third quarter 2018. Financial analysts and media are invited to participate in a telephone conference, which will include a pre...
Source: PR Newswire
Date: October, 23 2018 04:52
Sarepta in-licenses gene therapy for Sanfilippo A from Lysogene
Sarepta Therapeutics (NASDAQ: SRPT ) inks an agreement with French biotech Lysogene for exclusive ex-Europe rights to gene therapy LYS-SAF302 for the potential treatment of mucopolysaccharidosis type IIIA ( MPS IIIA ), also known as Sanfilippo syndrome type A, a rare progressive disorder a...
Source: SeekingAlpha
Date: October, 15 2018 08:31

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-14N/A22.90N/AN/A0
2018-12-13N/A22.90N/AN/A0
2018-12-12N/A22.90N/AN/A0
2018-12-11N/A22.90N/AN/A0
2018-12-10N/A22.90N/AN/A20

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-102020100.0000Short
2018-11-2922100.0000Short
2018-11-23500500100.0000Short
2018-11-15475475100.0000Short
2018-08-2915,25415,254100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BIOVF.


About Swedish Orphan Biovitrum AB (OTC: BIOVF)

Logo for Swedish Orphan Biovitrum AB (OTC: BIOVF)

Biovitrum is an international pharmaceutical company that markets specialist pharmaceuticals in several regions globally.

 

Contact Information

 

 

Current Management

  • Geoffrey McDonough / CEO
  • Annika Muskantor / CFO
  • Asa Stenqvist / VP, Investor Rel., VP, Corp. Comm.

Current Share Structure

  • Market Cap: $5,410,622,640 - 05/11/2018
  • Issue and Outstanding: 265,226,600 - 12/22/2011

 



Daily Technical Chart for (OTC: BIOVF)

Daily Technical Chart for (OTC: BIOVF)


Stay tuned for daily updates and more on (OTC: BIOVF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BIOVF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BIOVF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BIOVF and does not buy, sell, or trade any shares of BIOVF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/